Malaria

FDA creates medication guide for Lariam

Published in TB and Outbreaks Week, July 29th, 2003

The U.S. Food and Drug Administration (FDA) has announced the development of a Medication Guide (FDA-approved patient labeling) to provide better information to consumers about the risks and benefits of Lariam (mefloquine hydrochloride), and to educate patients on the measures to be taken to optimize Lariam's effectiveness.

Lariam is a valuable drug in helping to prevent malaria, but in rare instances it has been associated with serious psychiatric adverse events.

"The Lariam Medication Guide is an important new tool for managing the risks of Lariam, one of the most highly effective means of combating one of the deadliest diseases in the world," said...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2003-07-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry